vs
Side-by-side financial comparison of Atara Biotherapeutics, Inc. (ATRA) and CALLAN JMB INC. (CJMB). Click either name above to swap in a different company.
Atara Biotherapeutics, Inc. is the larger business by last-quarter revenue ($1.6M vs $1.2M, roughly 1.4× CALLAN JMB INC.).
Atara Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic T-cell immunotherapies for patients with unmet medical needs across oncology, autoimmune disease, and infectious disease indications. It operates primarily in North America, Europe, and Asia-Pacific, partnering with research institutions to advance its novel treatment pipeline.
ATRA vs CJMB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.6M | $1.2M |
| Net Profit | — | $-2.6M |
| Gross Margin | — | 30.3% |
| Operating Margin | — | -216.6% |
| Net Margin | — | -223.8% |
| Revenue YoY | -95.1% | — |
| Net Profit YoY | 73.2% | — |
| EPS (diluted) | — | $-0.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.6M | $1.2M | ||
| Q3 25 | $3.5M | $1.4M | ||
| Q2 25 | $17.6M | $1.7M | ||
| Q1 25 | $98.1M | $1.4M | ||
| Q4 24 | $32.8M | — | ||
| Q3 24 | $40.2M | — | ||
| Q2 24 | $28.6M | — | ||
| Q1 24 | $27.4M | — |
| Q4 25 | — | $-2.6M | ||
| Q3 25 | $-4.3M | $-2.7M | ||
| Q2 25 | $2.4M | $-1.4M | ||
| Q1 25 | $38.0M | $-1.2M | ||
| Q4 24 | $-12.7M | — | ||
| Q3 24 | $-21.9M | — | ||
| Q2 24 | $-19.0M | — | ||
| Q1 24 | $-31.8M | — |
| Q4 25 | — | 30.3% | ||
| Q3 25 | — | 34.1% | ||
| Q2 25 | — | 38.6% | ||
| Q1 25 | — | 42.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -216.6% | ||
| Q3 25 | -103.5% | -129.9% | ||
| Q2 25 | 18.2% | -84.2% | ||
| Q1 25 | 39.5% | -85.4% | ||
| Q4 24 | -37.3% | — | ||
| Q3 24 | -54.1% | — | ||
| Q2 24 | -63.7% | — | ||
| Q1 24 | -114.2% | — |
| Q4 25 | — | -223.8% | ||
| Q3 25 | -124.6% | -188.8% | ||
| Q2 25 | 13.6% | -83.9% | ||
| Q1 25 | 38.7% | -85.6% | ||
| Q4 24 | -38.8% | — | ||
| Q3 24 | -54.5% | — | ||
| Q2 24 | -66.5% | — | ||
| Q1 24 | -116.1% | — |
| Q4 25 | — | $-0.58 | ||
| Q3 25 | $-0.32 | $-0.61 | ||
| Q2 25 | $0.19 | $-0.31 | ||
| Q1 25 | $3.50 | $-0.32 | ||
| Q4 24 | $0.27 | — | ||
| Q3 24 | $-2.93 | — | ||
| Q2 24 | $-3.10 | — | ||
| Q1 24 | $-5.65 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $2.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-38.5M | $2.3M |
| Total Assets | $20.2M | $5.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $2.1M | ||
| Q3 25 | $13.7M | $2.8M | ||
| Q2 25 | $22.3M | $4.2M | ||
| Q1 25 | $13.8M | $5.2M | ||
| Q4 24 | $42.5M | — | ||
| Q3 24 | $67.2M | — | ||
| Q2 24 | $35.3M | — | ||
| Q1 24 | $46.2M | — |
| Q4 25 | $-38.5M | $2.3M | ||
| Q3 25 | $-36.6M | $4.2M | ||
| Q2 25 | $-35.0M | $5.8M | ||
| Q1 25 | $-55.1M | $6.8M | ||
| Q4 24 | $-97.3M | — | ||
| Q3 24 | $-90.5M | — | ||
| Q2 24 | $-110.9M | — | ||
| Q1 24 | $-98.3M | — |
| Q4 25 | $20.2M | $5.8M | ||
| Q3 25 | $30.2M | $7.7M | ||
| Q2 25 | $36.9M | $9.0M | ||
| Q1 25 | $62.0M | $8.5M | ||
| Q4 24 | $109.1M | — | ||
| Q3 24 | $142.7M | — | ||
| Q2 24 | $117.3M | — | ||
| Q1 24 | $165.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-50.9M | $-659.0K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-50.9M | $-659.0K | ||
| Q3 25 | $-9.8M | $-1.8M | ||
| Q2 25 | $-7.3M | $-563.3K | ||
| Q1 25 | $-28.1M | $-1.6M | ||
| Q4 24 | $-24.5M | — | ||
| Q3 24 | $-4.0M | — | ||
| Q2 24 | $-10.6M | — | ||
| Q1 24 | $-29.6M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-1.9M | ||
| Q2 25 | — | $-995.8K | ||
| Q1 25 | — | $-1.6M | ||
| Q4 24 | $-24.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-10.7M | — | ||
| Q1 24 | $-29.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -133.5% | ||
| Q2 25 | — | -59.8% | ||
| Q1 25 | — | -108.8% | ||
| Q4 24 | -75.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -37.3% | — | ||
| Q1 24 | -108.7% | — |
| Q4 25 | 0.0% | 0.0% | ||
| Q3 25 | 0.0% | 11.7% | ||
| Q2 25 | 0.0% | 26.0% | ||
| Q1 25 | 0.0% | 1.0% | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -3.07× | — | ||
| Q1 25 | -0.74× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATRA
Segment breakdown not available.
CJMB
| Governmental | $1.1M | 91% |
| Other | $106.5K | 9% |
